GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (BSP:T1CH34) » Definitions » Cyclically Adjusted Price-to-FCF

Bio-Techne (BSP:T1CH34) Cyclically Adjusted Price-to-FCF : 32.38 (As of Jun. 06, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Bio-Techne Cyclically Adjusted Price-to-FCF?

As of today (2025-06-06), Bio-Techne's current share price is R$9.39. Bio-Techne's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was R$0.29. Bio-Techne's Cyclically Adjusted Price-to-FCF for today is 32.38.

The historical rank and industry rank for Bio-Techne's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

BSP:T1CH34' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 27.2   Med: 53.38   Max: 125.91
Current: 33.43

During the past years, Bio-Techne's highest Cyclically Adjusted Price-to-FCF was 125.91. The lowest was 27.20. And the median was 53.38.

BSP:T1CH34's Cyclically Adjusted Price-to-FCF is ranked better than
63.11% of 103 companies
in the Biotechnology industry
Industry Median: 49.09 vs BSP:T1CH34: 33.43

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Bio-Techne's adjusted free cash flow per share data for the three months ended in Mar. 2025 was R$0.037. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is R$0.29 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Bio-Techne Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Bio-Techne's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Cyclically Adjusted Price-to-FCF Chart

Bio-Techne Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71.20 105.22 70.00 61.83 51.27

Bio-Techne Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.81 51.27 56.73 50.40 40.60

Competitive Comparison of Bio-Techne's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Bio-Techne's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Techne's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Cyclically Adjusted Price-to-FCF falls into.


;
;

Bio-Techne Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Bio-Techne's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=9.39/0.29
=32.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Techne's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Bio-Techne's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.037/134.9266*134.9266
=0.037

Current CPI (Mar. 2025) = 134.9266.

Bio-Techne Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.021 100.684 0.028
201509 0.022 100.392 0.030
201512 0.029 99.792 0.039
201603 0.028 100.470 0.038
201606 0.026 101.688 0.034
201609 0.017 101.861 0.023
201612 0.029 101.863 0.038
201703 0.015 102.862 0.020
201706 0.033 103.349 0.043
201709 0.027 104.136 0.035
201712 0.024 104.011 0.031
201803 0.013 105.290 0.017
201806 0.048 106.317 0.061
201809 0.031 106.507 0.039
201812 0.035 105.998 0.045
201903 0.029 107.251 0.036
201906 0.036 108.070 0.045
201909 0.026 108.329 0.032
201912 0.048 108.420 0.060
202003 0.041 108.902 0.051
202006 0.030 108.767 0.037
202009 0.062 109.815 0.076
202012 0.083 109.897 0.102
202103 0.074 111.754 0.089
202106 0.113 114.631 0.133
202109 0.045 115.734 0.052
202112 0.104 117.630 0.119
202203 0.059 121.301 0.066
202206 0.092 125.017 0.099
202209 0.050 125.227 0.054
202212 0.063 125.222 0.068
202303 0.042 127.348 0.044
202306 0.072 128.729 0.075
202309 0.047 129.860 0.049
202312 0.070 129.419 0.073
202403 0.067 131.776 0.069
202406 0.064 132.554 0.065
202409 0.063 133.029 0.064
202412 0.098 133.157 0.099
202503 0.037 134.927 0.037

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bio-Techne  (BSP:T1CH34) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Bio-Techne Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne Business Description

Industry
Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne Headlines

No Headlines